ROIVANT SCIENCES LTD. (ROIV) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2024-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2024-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2024-06-30..
Borrowing debt
Overview →Financial period ending 2024-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2024-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2024-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2024-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 12.00M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | (m) | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 6.50B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | (m) | (m) | $12.00M | (m) | (m) | (m) | $6.50B | (m) |
| 2024-03-31 | (m) | (m) | $12.00M | (m) | (m) | (m) | $7.22B | (m) |
| 2023-12-31 | (m) | (m) | $45.71M | (m) | (m) | (m) | $7.31B | (m) |
| 2023-09-30 | (m) | (m) | $49.00M | (m) | (m) | (m) | $2.07B | (m) |
| 2023-06-30 | (m) | (m) | $44.41M | (m) | (m) | (m) | $2.14B | (m) |
| 2023-03-31 | (m) | (m) | $40.72M | (m) | (m) | (m) | $2.39B | (m) |
| 2022-12-31 | (m) | (m) | $37.72M | (m) | (m) | (m) | $2.20B | (m) |
| 2022-09-30 | (m) | (m) | $35.75M | (m) | (m) | (m) | $2.22B | (m) |
| 2022-03-31 | (m) | (m) | $0.00 | $210.03M | (m) | (m) | $2.59B | (m) |
| 2021-12-31 | (m) | (m) | $0.00 | $204.04M | (m) | (m) | $2.80B | (m) |
| 2021-09-30 | (m) | (m) | $0.00 | $199.87M | (m) | (m) | $3.10B | (m) |
| 2021-06-30 | (m) | (m) | $0.00 | $186.35M | (m) | (m) | $2.45B | (m) |
| 2021-03-31 | (m) | (m) | $0.00 | $170.28M | (m) | (m) | $2.59B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |